HomeCompareHCDIQ vs PFE

HCDIQ vs PFE: Dividend Comparison 2026

HCDIQ yields 1000000.00% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HCDIQ wins by $4.7683925249533696e+36M in total portfolio value
10 years
HCDIQ
HCDIQ
● Live price
1000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.7683925249533696e+36M
Annual income
$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00
Full HCDIQ calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — HCDIQ vs PFE

📍 HCDIQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHCDIQPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HCDIQ + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HCDIQ pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HCDIQ
Annual income on $10K today (after 15% tax)
$85,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, HCDIQ beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HCDIQ + PFE for your $10,000?

HCDIQ: 50%PFE: 50%
100% PFE50/50100% HCDIQ
Portfolio after 10yr
$2.3841962624766848e+36M
Annual income
$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

HCDIQ
No analyst data
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HCDIQ buys
0
PFE buys
0
No recent congressional trades found for HCDIQ or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHCDIQPFE
Forward yield1000000.00%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$4.7683925249533696e+36M$49.6K
Annual income after 10y$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$26,258.71
Total dividends collected$4.7683311610149396e+36M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: HCDIQ vs PFE ($10,000, DRIP)

YearHCDIQ PortfolioHCDIQ Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$100,010,700$100,000,000.00$9,153$693.39+$100.00MHCDIQ
2$934,786,450,701$934,679,439,252.34$8,593$849.25+$934786.44MHCDIQ
3$8,165,787,108,578,292$8,164,786,887,076,042.00$8,336$1,066.78+$8165787108.57MHCDIQ
4$66,665,884,190,957,650,000$66,657,146,798,751,470,000.00$8,437$1,384.80+$66665884190957.64MHCDIQ
5$508,662,171,058,048,100,000,000$508,590,838,561,963,700,000,000.00$9,013$1,875.40+$508662171058048128.00MHCDIQ
6$3,627,235,248,428,489,700,000,000,000$3,626,690,979,905,457,600,000,000,000.00$10,306$2,680.72+$3.62723524842849e+21MHCDIQ
7$24,173,681,159,150,610,000,000,000,000,000$24,169,800,017,434,790,000,000,000,000,000.00$12,820$4,101.38+$2.417368115915061e+25MHCDIQ
8$150,567,402,861,454,640,000,000,000,000,000,000$150,541,537,022,614,370,000,000,000,000,000,000.00$17,673$6,826.70+$1.5056740286145463e+29MHCDIQ
9$876,477,100,281,847,600,000,000,000,000,000,000,000$876,315,993,160,785,800,000,000,000,000,000,000,000.00$27,543$12,591.86+$8.764771002818475e+32MHCDIQ
10$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$49,560$26,258.71+$4.7683925249533696e+36MHCDIQ

HCDIQ vs PFE: Complete Analysis 2026

HCDIQStock

Harbor Custom Development, Inc. operates as a real estate development company in Washington, California, Texas, and Florida. The company is involved in land development cycle, which includes land acquisition, entitlement, development, and construction of project infrastructure; single and multi-family vertical construction; and marketing and sale of various residential projects. It also undertakes projects, such as residential lots, home communities, townhomes, and multi-story apartment properties. The company was formerly known as Harbor Custom Homes, Inc. and changed its name to Harbor Custom Development, Inc. in August 2019. Harbor Custom Development, Inc. was incorporated in 2014 and is headquartered in Tacoma, Washington. On December 11, 2023, Harbor Custom Development, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Western District of Washington.

Full HCDIQ Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this HCDIQ vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HCDIQ vs SCHDHCDIQ vs JEPIHCDIQ vs OHCDIQ vs KOHCDIQ vs MAINHCDIQ vs JNJHCDIQ vs MRKHCDIQ vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.